Department of Clinical Pharmacy (A.O.), University of California, San Francisco, CA.
Institute for Human Genetics (A.O., T.J.H., N.R.), University of California, San Francisco, CA.
Circ Genom Precis Med. 2018 Sep;11(9):e002043. doi: 10.1161/CIRCGEN.117.002043.
Low-density lipoprotein cholesterol (LDL-C) response to statin therapy has not been fully elucidated in real-world populations. The primary objective of this study was to characterize statin LDL-C dose-response and its heritability in a large, multiethnic population of statin users.
We determined the effect of statin dosing on lipid measures utilizing electronic health records in 33 139 statin users from the Kaiser Permanente GERA cohort (Genetic Epidemiology Research on Adult Health and Aging). The relationship between statin defined daily dose and lipid parameter response (percent change) was determined.
Defined daily dose and LDL-C response was associated in a log-linear relationship (β, -6.17; SE, 0.09; P<10) which remained significant after adjusting for prespecified covariates (adjusted β, -5.59; SE, 0.12; P<10). Statin type, sex, age, smoking status, diabetes mellitus, and East Asian race/ethnicity were significant independent predictors of statin-induced changes in LDL-C. Based on a variance-component method within the subset of statin users who had at least 1 first-degree relative who was also a statin user (n=1036), heritability of statin LDL-C response was estimated at 11.7% (SE, 8.6%; P=0.087).
Using electronic health record data, we observed a statin LDL-C dose-response consistent with the rule of 6% from prior clinical trial data. Clinical and demographic predictors of statin LDL-C response exhibited highly significant but modest effects. Finally, statin-induced changes in LDL-C were not found to be strongly inherited. Ultimately, these findings demonstrate (1) the utility of electronic health records as a reliable source to generate robust phenotypes for pharmacogenomic research and (2) the potential role of statin precision medicine in lipid management.
他汀类药物治疗后的低密度脂蛋白胆固醇(LDL-C)反应在真实人群中尚未得到充分阐明。本研究的主要目的是描述他汀类药物使用者中大量多民族人群的他汀类药物 LDL-C 剂量反应及其遗传性。
我们利用 Kaiser Permanente GERA 队列(成人健康与衰老的遗传流行病学研究)的电子健康记录确定了 33139 名他汀类药物使用者的他汀类药物剂量对血脂指标的影响。确定了他汀类药物定义的每日剂量与脂质参数反应(百分比变化)之间的关系。
定义的每日剂量和 LDL-C 反应呈对数线性关系(β,-6.17;SE,0.09;P<10),在调整了预先指定的协变量后仍然显著(调整β,-5.59;SE,0.12;P<10)。他汀类药物类型、性别、年龄、吸烟状况、糖尿病和东亚种族/民族是他汀类药物引起的 LDL-C 变化的显著独立预测因素。基于至少有 1 名一级亲属也是他汀类药物使用者的他汀类药物使用者子集(n=1036)中的方差分量方法,他汀类药物 LDL-C 反应的遗传率估计为 11.7%(SE,8.6%;P=0.087)。
使用电子健康记录数据,我们观察到他汀类药物 LDL-C 剂量反应与先前临床试验数据的 6%规则一致。他汀类药物 LDL-C 反应的临床和人口统计学预测因素表现出高度显著但适度的影响。最后,他汀类药物引起的 LDL-C 变化并未被发现具有很强的遗传性。最终,这些发现表明(1)电子健康记录作为生成用于药物基因组学研究的稳健表型的可靠来源的实用性,以及(2)他汀类药物精准医学在脂质管理中的潜在作用。